Rebiopsie tumorale : quand ? pour qui ? pourquoi ? comment ? DOI
Vincent Fallet

Revue des Maladies Respiratoires Actualités, Journal Year: 2023, Volume and Issue: 15(2), P. 2S121 - 2S129

Published: Oct. 1, 2023

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study DOI
Yuankai Shi,

Yanzhen Guo,

Xingya Li

et al.

The Lancet Respiratory Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease DOI
W. Marston Linehan, Justin F. Gainor, Vincent K. Lam

et al.

Cancer Discovery, Journal Year: 2024, Volume and Issue: 14(6), P. 915 - 919

Published: June 3, 2024

Summary: Drug-tolerant residual disease (DTRD) after the initial maximal response to a systemic therapy can serve as tumor reservoir for development of acquired drug resistance and represents major clinical challenge across various cancers types therapies. To unlock next frontier in precision oncology, we propose fundamental paradigm shift treatment metastatic with sharpened focus towards defining, monitoring, therapeutically targeting DTRD state.

Language: Английский

Citations

7
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2 DOI
Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 12, 2024

.

Citations

5
Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group DOI
Lore Decoster,

D.R. Camidge,

J. Fletcher

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: 200, P. 108087 - 108087

Published: Jan. 13, 2025

Language: Английский

Citations

0
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 DOI
Dwight H. Owen, Nofisat Ismaila,

Amith Ahluwalia

et al.

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual . follow Conflict of Interest Policy Implementation Clinical Practice and updates not intended to substitute independent professional judgment treating clinician do account individual variation among patients. See appendix disclaimers other important information ( Appendix 1 2 ). Updates published regularly can be found at https://ascopubs.org/nsclc-da-living-guideline

Language: Английский

Citations

0
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 DOI
Natasha B. Leighl, Nofisat Ismaila, Greg Andrew Durm

et al.

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual . follow Conflict of Interest Policy Implementation Clinical Practice and updates not intended to substitute independent professional judgment treating clinician do account individual variation among patients. See appendix disclaimers other important information ( Appendix 1 2 ). Updates published regularly can be found at https://ascopubs.org/nsclc-non-da-living-guideline

Language: Английский

Citations

0
Interplay of Metastasis, Cancer Stem Cells, and Energy Metabolism in Cancer Progression DOI
Arijit Mal

Current Tissue Microenvironment Reports, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Language: Английский

Citations

0
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study DOI
Akito Miyazaki, Kei Kunimasa, Toshitaka Morishima

et al.

ESMO Real World Data and Digital Oncology, Journal Year: 2025, Volume and Issue: 8, P. 100137 - 100137

Published: April 14, 2025

Language: Английский

Citations

0
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study DOI
C. Chouaïd, L. Bosquet, Craig Knott

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: 203, P. 108548 - 108548

Published: April 19, 2025

Language: Английский

Citations

0
CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression DOI

Wesley K.Y. Wong,

Kevin Mok, G. Tsui

et al.

Clinical Lung Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0